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The biliary tree consists of intrahepatic and extrahepatic bile ducts and is lined by biliary epithelial cells (or cholangiocytes). There
are also peribiliary glands around the intrahepatic large bile ducts and extrahepatic bile ducts. The biliary tree is a conduit of bile
secretedbyhepatocytesandbiliaryepithelialcellsandalsooftheperibiliaryglandsandhasseveralphysiologicalroles.Anumberof
diseases aﬀect mainly the intrahepatic and extrahepatic biliary tree, and, in this special issue, these cholangiopathies are reviewed
in detail with respect to genetics, pathogenesis, and pathology. In this paper, the anatomy and physiology of the biliary tree, basic
injuries to biliary epithelial cells from stress and bile duct damage, and representative cholangiopathies are brieﬂy reviewed.
1.Introduction
A number of diseases aﬀect the biliary tree (cholan-
giopathies), though the pathological mechanisms involved
and the anatomical level of the biliary tree aﬀected vary
[1]. For example, small interlobular bile ducts are mainly
aﬀected by a Th1-dominated microenvironment and cell-
mediated immune response in PBC [2], while a Th2-
dominated microenvironment and increased numbers of
regulatory T cells are the major features of IgG4-related
sclerosing cholangitis which aﬀects mainly the extrahepatic
bile ducts [3]. Ischemic damage to the biliary tree is a serious
complication in liver transplantations [4].
In this special issue, cholangiopathy with respect to
genetics, pathogenesis, and pathology will be discussed in
detail.Herein,theanatomyandphysiologyofthebiliarytree,
basic injuries to biliary epithelial cells, basic forms of bile
duct damage, and etiological classiﬁcations of cholangiopa-
thy are reviewed. This tutorial review will be helpful for a
better understanding of cholangiopathy.
2. Anatomy and Characteristicsof the
Biliary Tree
2.1. Anatomy. The biliary tree is composed of extrahepatic
and intrahepatic bile ducts [5]. The former include the
right and left hepatic ducts and their conﬂuence and the
common hepatic. and bile ducts, while the latter include the
bile ducts proximal to the right or left hepatic duct. The
intrahepatic branching of the bile ducts is best visualized
on a cholangiograph or biliary injection cast (Figures 1 and
2). The extrahepatic bile duct is lined by high columnar
epithelial cells, and its wall is composed of dense collagenous
tissue harboring scattered smooth muscular elements.
The intrahepatic bile ducts can be classiﬁed as large and
small, though there is no sharp delineation of the various
segments [1, 5]. The biliary epithelial cells or cholangiocytes
compose approximately 4-5% of liver mass. The large type
consists of the right and left hepatic bile ducts and their
ﬁrst to third branches (segmental and area bile ducts). These
ductsaregrosslyvisibleandbelongtotheperihilarbileducts.
Theyarelinedbyatallcolumnarepitheliumandsurrounded
by a dense hypocellular collagenous duct wall. In contrast,
small intrahepatic bile ducts, the branches of the large intra-
hepatic bile duct, are classiﬁed into septal and interlobular
bile ducts which are visible only under a microscope. While
the septal ducts (>100μm in diameter) are lined by tall
columnar cells with basal nuclei, the interlobular bile ducts
are lined by cuboidal cells. The ﬁbrous ductal wall is evident
in the former like large intrahepatic ducts, but not in the
latter. The interlobular bile ducts are connected to the bile
canalicular network by ductules (<20μm diameter) lined by
no more than a few minimally diﬀerentiated cuboidal cells
and the canals of Hering, which are lined partly by biliary2 International Journal of Hepatology
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Figure 1: Biliary cast of normal liver. C: common hepatic duct, L:
left hepatic duct, and R: right hepatic duct.
CHD
Figure 2: Diagram of the biliary tree. Red: right and left hepatic
duct and their conﬂuence, yellow: branches of the right or left
hepatic ducts, and black: further branches. CHD: common hepatic
duct.
epithelium and partly by hepatocytes. The intrahepatic stem
cellnichesarethecanalsofHeringinpostnatallivers[6].Bile
ductules are very reactive anatomical elements in the liver,
and proliferating bile ductules are reportedly involved in the
ﬁbrous progression of various chronic liver diseases and are
easily identiﬁable by immunostaining of biliary cytokeratin
( C K7a n d1 9 ) .
Peribiliary glands, the third biliary component, are
present within the ﬁbromuscular walls of extrahepatic bile
ducts and also along the large intrahepatic bile ducts [1, 5,
7]. Glandular elements are also found at the neck of the
gallbladder. Peribiliary glands around the large intrahepatic
bile ducts (Figure 3) are subdivided into intramural glands,
nonbranching tubular glands, and extramural ramiﬁed
glands. The latter lie in the periductal connective tissue and,
in a three-dimensional model, have a linear distribution
along the opposite sides of the bile ducts and indirectly drain
into the bile duct lumen via their own conduit. The extra-
mural glands consist of serous and mucous acini. Pancreatic
acini without Langerhans’ islets are found intermingled with
peribiliary glandular acini and are probably an intrinsic
component of these glands. The glands are thought to have
secretory activities. The extrahepatic stem cell niches are the
peribiliaryglandsdeepwithinthewallsofthebileduct[6,8].
B
Figure 3: Peribiliary glands. B: bile duct; arrows: peribiliary glands
and their conduits.
2.2. Distribution of Antigens along the Biliary Tree. The
individual anatomical components of the biliary tree each
have a rather characteristic antigen, probably reﬂecting a
site-speciﬁc function [9, 10]. For example, the BECs lining
large bile ducts are columnar and mucus is detectable in
the supranuclear cytoplasm, but mucin is not detectable in
the interlobular bile ducts and bile ductules. In contrast,
in the adult liver, the BECs of intrahepatic large bile
ducts constantly express MUC3, a membrane-binding type,
whereas those of small bile ducts do not. MUC6 is constantly
and focally expressed in BECs in the intrahepatic large bile
ducts in normal liver. The expression of MUC1, MUC2,
and MUC5 was infrequent in normal livers but increased
in hepatolithiasis [9]. This study disclosed that the normal
biliary tree has a speciﬁc expression of blood group antigens
at diﬀerent levels and that this expression is altered under
pathologic conditions. In normal livers, large and septal
bile ducts expressed A and B antigens in patients with
comparable blood groups and also expressed H antigen
frequently in patients with blood group O, A, or B and
infrequently in patients with type AB. Lea and Leb are
expressedinBECsatan ylev elinsecretors.Asforcytok eratin,
CK7 and CK19 are expressed in BECs of the biliary tree and
also in peribiliary glands, while EpCAM is expressed in bile
d u c t u l e s .C K 8a n d1 8a r ee x p r e s s e di nh e p a t o c y t e sa n da l s o
BECs of the biliary tree.
2.3. Supply of Blood to the Biliary Tree. The intrahepatic
and extrahepatic biliary tract is supplied by a network
of ﬁne vessels called the peribiliary vascular plexus (PBP)
which exclusively derives from hepatic arterial branches
[11–13]. The PVP can be histologically divided into the
inner, intermediate, and outer layers, with respect to the
bile duct walls [12]. These three layers are well and poorly
developed in the large intrahepatic bile ducts and septal bile
ducts, respectively, although the PBP around the interloblar
bile ducts and bile ductules consists of scattered capillaries
with no discernible layers [13]. This plexus has a fern-like
appearance around the bile duct under the scanning electron
microscope. The PBP drains into the sinusoids through
“radicular portal veins” or communicates with portal venousInternational Journal of Hepatology 3
branchesthrough“internalroots”ordirectlyintothehepatic
sinusoids in animals and probably in humans.
The inner layer, a layer of capillaries, is found just
beneaththebasementmembraneoftheepitheliallayerandis
regularly distributed like a chain. Ultrastructurally, the inner
capillary layers are composed of fenestrated endothelial cells,
and the number of fenestrae with a thin diaphragm is rather
high on the capillary side facing the bile duct epithelium
[13]. These observations suggest that the PBP, particularly
the inner layer, may participate in the physiology of the bile
ducts, particularly in the exchange of substances between
blood in the peribiliary vascular plexus and bile in the bile
ducts and in the supply and drainage of substances to and
from the biliary epithelia [12].
2.4. Physiological Roles of the Biliary Tree. The biliary tree is
lined by specialized epithelial cells called BECs or cholan-
giocytes [14] and is not only a conduit of bile secreted
by hepatocytes and cholangiocytes but also a conduit of
the peribiliary glands. The bile ducts and peribiliary glands
play a number of physiological roles in the biliary system,
contributing to about one-third of total bile secretion, par-
ticipating in bile acid and water reabsorption, and secretion
via transporters, and also mediating immune responses
including innate immunity [15]. The primary hepatic bile
secreted by hepatocytes is modiﬁed by BECs via a series of
secretory and absorptive processes that provide additional
bile water (BECs secrete ∼40% of daily bile production
in humans) or secrete HCO3
− to induce an alkakine state
[14]. BECs also interact with the immune system and
microorganisms and are also involved in drug metabolism.
To accomplish these functions, BECs display morphological
and functional heterogeneity along the biliary tree.
2.5. Innate Immunity. The biliary tree is essentially sterile
under normal conditions, but bile is potentially contami-
nated by bacterial components such as pathogen-associated
molecular patterns (PAMPs) including lipopolysaccharide
(LPS) and bacterial DNA originating from intestinal ﬂora,
which are actually detectable in bile of patients with chronic
inﬂammatory biliary diseases [16]. In this context, the
biliary tract is equipped with defence mechanisms, which are
physical (bile ﬂow and biliary mucus), chemical (bile salts),
and immunological, such as secretory IgA. BECs also express
Toll-likereceptors(TLR)andintracellularadaptormolecules
and secrete antibiotic peptides and (pro)inﬂammatory
cytokines, thereby participating in the defense of the bile
ducts [15].
Nonspeciﬁc bactericidal enzymes such as lactoferrin and
lysozyme are also detected in the intrahepatic biliary tree,
peribiliary glands, and bile [15]. Human β-defensins (hBDs)
and cathelicidin, another antimicrobial peptide contributing
to innate immunity at mucosal surfaces, are expressed in the
biliary tree. hBD-1 is constitutively expressed in the biliary
epithelium, while hBD-2 is expressed in large intrahepatic
bile ducts in extrahepatic biliary obstruction, hepatolithiasis,
and, to a lesser degree, PBC and PSC, suggesting a response
to local infection or bacterial components, cytokines such as
IL-1β and TNF-α, and/or active inﬂammation. Cathelicidin
is expressed by normal biliary epithelial cells in addition to
hepatocytes. Trefoil factor family (TFF) 1, 2, and 3 peptides
expressed at the apical surface of the epithelium play a major
role in mucosal repair.
IgA is known to be secreted into bile by binding with
the secretory component (SC), and secretory IgA (SIgA)
functions in a number of ways to protect the biliary tract.
For example, it can directly bind and neutralize bacterial
toxins. SIgA can bind to bacteria and prevent their adhesion
to the mucosal membrane. Additionally, IgA has been
demonstrated to neutralize intracellular microbes and their
products. Biliary intraepithelial lymphocytes (bIELs), which
are markedly increased in immune-mediated cholangitis,
are occasionally encountered in normal intrahepatic bile
ducts. Most of them are positive for CD8, some are positive
for CD57, and these cells may participate in biliary innate
immunity [17].
3.BasicInjuriesof BiliaryEpithelial
Cellsand Bile DuctDamage
3.1. Basic Injuries of BECs. Several pathologic agents and
stress aﬀect the intrahepatic and extrahepatic biliary tree
including viral, bacterial, and even parasitic infections,
oxidativestress,andimmunologicalassaults,aswellasbiliary
epithelial injuries from necrosis, apoptosis, and hyperplasia,
and also bile duct damages.
3.1.1. Apoptosis and Necrosis. In some biliary diseases such
as primary biliary cirrhosis (PBC) and chronic ductopenic
allograft rejection, the ongoing apoptosis of BECs is impor-
tant for progressive bile duct loss. In H&E stained sections,
eosinophilic, shrunken slender cells with pyknotic nuclei in
the biliary epithelial layer and fragmented and condensed
nuclei in the bile duct lumen can be regarded as apoptotic
bodies[2,15].Electronmicroscopically,shrunkenBECswith
a condensed cytoplasm and pyknotic nuclei are a marker of
apoptosis. Apoptosis of BECs can be conﬁrmed using in situ
nick-end labelling and immunostaining of single stranded
DNA, both of which detect DNA fragmentation. In contrast,
the coagulative or lytic necrosis of the biliary epithelium is
occasionally encountered in toxic cholangiopathy [18].
3.1.2. Cellular Senescence. Senescent BECs show character-
istic features such as an eosinophilic cytoplasm, cellular
and nuclear enlargement, multinucleation, and an irregular
arrangement with uneven nuclear spacing [19]. Actually,
these cells also express cellular senescent markers such as
the cell cycle regulators, p16INK4 and p21WAF1/CIP ,a n d
increased activity of senescence-associated β-galactosidase
(SA-β-gal). Recent studies showed that cellular senescence
has at least two pathological eﬀects in the development
of biliary diseases: impaired regeneration and senescence-
associated secretory phenotypes (SASPs).
Impaired Regeneration. Senescent cells no longer have the
ability to proliferate and they are irreversibly arrested at4 International Journal of Hepatology
the G1 phase of the cell cycle [20]. The expression of
senescence-related markers is increased in BECs during early
chronic rejection in chronic liver allograft and PBC. Cellular
senescence of BECs is involved in impaired regeneration and
eventual and progressive bile duct loss in PBC and duc-
topenic chronic rejection [21, 22]. A relatively insuﬃcient
proliferative response of BECs due to cellular senescence (see
below)isalsoresponsiblefortheprogressivelossofbileducts
due to apoptosis.
Senescence-Associated Secretory Phenotypes. Accumulating
evidence suggests that senescent cells remain metabolically
active and play an important role in modulating the
microenvironment around them by secreting cytokines,
chemokines, growth factors, and proﬁbrogenic factors [19].
For example, senescent BECs of PBC expressing CCL2 and
CX3CL1 may be involved in the recruitment of monocytes
and possibly T lymphocytes into portal tracts, around
injured and senescent BECs, and thereby responsible for the
development of immune-mediated cholangitis such as PBC
[19, 23].
3.1.3. Biliary Epithelial Cell Renewal. The homeostasis of
physiological and pathological biliary epithelia operates
through a balance between cell loss and cell renewal. Cell
loss in the biliary epithelium is mainly due to apoptosis
or senescence and mostly regulated by the bcl-2 family of
proteins or senescence-associated factors such as p16 and
p21. The biliary epithelial cells of bile ductules or small bile
ducts may be replenished by bile ductular cells or hepatic
progenitorcellsinthecanalofHering,thoughsuchprocesses
may be unlikely in the intrahepatic large bile ducts. As
mentioned, the peribiliary glands themselves or progenitor
cells located in these glands may be involved in renewal of
the biliary epithelium of intrahepatic large bile ducts and
extrahepatic bile ducts and also proliferation of the epithelia
lining these bile ducts [7, 8].
3.1.4. Biliary Epithelial Hyperplasia. Inhibition of the apop-
totic or senescent process in the biliary epithelia may cause
hyperplasia with an increased risk of neoplastic transforma-
tion [24]. Hyperplasia of lining epithelia of the septal and
large bile ducts manifests as micropapillary projections or as
astratiﬁcationoftheepitheliumwithorwithoutdilatationof
theductlumen.Peribiliaryglands,intramuralorextramural,
also show hyperplasia and proliferation and participate in
the secretion of neutral, carboxylated, and sulphated mucins
into the bile duct lumen. When prominent, in particular
withClonorchissinensisinfectionsorhepatolithiasis,theterm
adenomatoushyperplasiaorchronicproliferativecholangitis
has been used. As for the proliferation and hyperplasia of
bile ductules and small interlobular bile ducts, they appear
tourtous and increase in their number in the portal tracts.
Some of these lesions are included in the so-called ductular
reactions [25].
3.1.5.Metaplasia. Severalkindsofmetaplasiaarereportedin
the biliary epithelium of the intra- and extrahepatic biliary
tree, usually in cases of chronic biliary diseases such as
hepatolithiasis, parasitic cholangitis, and primary sclerosing
cholangitis (PSC). Gastrointestinal metaplasia resembling
pyloric glands and goblet cells is not infrequently seen in
chronically inﬂamed large bile ducts and peribiliary glands.
This change is associated with the aberrant expression of
gastric type mucus core protein (MUC) 5AC and MUC6
and also intestinal type MUC2. Such gastric and intestinal
mucin is involved in lithogenesis in hepatolithiasis [9]. The
so-called intramural glands with a gastric pyloric gland-like
appearance are increased in long-standing biliary diseases
and may reﬂect invagination of the biliary epithelium
with gastrointestinal metaplasia. Goblet cells are occasionally
encountered among bile duct-lining cells and also in peri-
biliary glands. Intestinal metaplasia with Paneth cells may
also be encountered in the peribiliary glands. The expression
of other molecules in intrahepatic large bile ducts, such as
REG I and trefoil factors, appears to be related to intestinal
or gastric metaplasia. While pancreatic acinar metaplasia is
also reported infrequently in PSC, its diﬀerentiation from
heterotopic pancreatic acini is controversial. Hepatocytic
metaplasia occurs in interlobular bile ducts and bile ductules
in various pathological situations but remains of unknown
signiﬁcance. Squamous metaplasia is rarely encountered in
long-standing inﬂammation of large bile ducts such as PSC
or in the lining of biliary cysts.
3.1.6. Biliary Intraepithelial Neoplasm (BilIN). Chronic bil-
iary diseases such as hepatolithiasis and PSC are occasionally
complicated by cholangiocarcinoma. In such cases, dysplas-
tic or early neoplastic lesions are known to precede the
invasive cholangiocarcinoma. Such biliary epithelial lesions
are known as dysplasia or atypical hyperplasia of the
biliary epithelium and characterized by atypical, enlarged,
and hyperchromatic nuclei, an increased nucleocytoplasmic
ratio, and a loss of polarity [5, 26]. Usually either micropap-
illary or ﬂat lesions aﬀect a portion or the circumference of
the bile duct. These lesions were proposed to be called biliary
intraepithelial neoplasm (BilIN), and this terminology was
recently adopted by WHO [26]. They are divided into three
grades according to cellular and structural atypia; BilIN-1,
BilIN -2, and BilIN -3. In BilIn-1, cellular/nuclear atypia are
mild or moderate but not enough for overt malignancy, and
cellular polarity is minimally disturbed and corresponding
to low-grade dysplasia. In BilIN-2, cellular/nuclear atypia
are evident but not marked enough for overt malignancy,
and the disturbance of cellular polarity is mild or focal,
corresponding to high-grade dysplasia. BlIN-3 shows cellu-
lar/nuclear atypia corresponding to overt malignancy, and
cellular polarity is diﬀusely disturbed, corresponding to a
so-called carcinoma in situ of the biliary tract [26]. BilIN-1,
BilIN -2, and BilIN -3 are seen in both large intrahepatic and
extrahepatic bile ducts, peribiliary glands, and gallbladder
and considered to reﬂect a multistep neoplastic transforma-
tion of the biliary epithelium.International Journal of Hepatology 5
3.2. Basic Pathology of Bile Duct Damage. In the biliary
tree, there are several types of bile duct damage such as
cholangiopathies and cholangitis. Representative pathologi-
cal features of the biliary tree are as follows.
3.2.1. Cholangitis and Its Classiﬁcation. Cholangitis is char-
acterized by biliary epithelial damage with inﬂammatory cell
inﬁltration. Some cholangitis is also associated with ductal
and periductal ﬁbrosis. It occurs along the biliary tree, and
the term cholangitis is used for inﬂammatory damage to bile
ductules.
Cholangitis can be histologically classiﬁed into suppu-
rative and nonsuppurative forms. Suppurative cholangitis
implies the presence of numerous polymorphonuclear cells
around and within the wall as well as within the lumen of the
ducts. This may involve ducts of any size and is occasionally
associated with abscess formation—cholangitic abscess. A
microbial infection is often responsible, but the change also
occurs in the presence of sterile bile, particularly after bile
extravasation. The release of chemokines or cytokines is the
likely cause in some cases.
“Nonsuppurative cholangitis” includes a spectrum of bile
ductinﬂammationwhichmaybegranulomatouscholangitis,
lymphoid cholangitis, ﬁbrous cholangitis, and pleomorphic
cholangitis according to the predominant type of inﬂamma-
tory reaction present [27]. Granulomatous cholangitis almost
always seems to be destructive. This type involving the
interlobular bile ducts constitutes the hallmark of PBC and
is also found in drug-induced liver disease and sarcoidosis.
The other types can be either destructive or nondestructive.
Lymphoid cholangitis refers to a close association between
duct branches, usually interlobular bile ducts, and lympho-
cytic aggregates, which may show a follicular arrangement.
This is found in PBC and PSC with concomitant bile
duct destruction or in nonbiliary disorders, in particular
autoimmune and viral hepatitis C. Pleomorphic cholangitis is
associatedwithinﬂammatorycellinﬁltration.Allothertypes
of cholangitis are found in CAH, PBC, PSC, and other liver
diseases. Fibrous cholangitis (also called sclerosing cholangitis)
with evident ductal ﬁbrosis develops as a consequence
of long-standing bile duct inﬂammatory, obstruction, or
ischemic injury; it can be obliterative or nonobliterative.
BECs show variable damage. The former is characteristic of
PSC, though, in our experience, it may be seen in acquired
forms of sclerosing cholangitis too. BECs of obliterative type
areactuallylostinﬁbrouslesions,appearingasaﬁbrouscore.
Sclerosing cholangitis with bile duct obliteration suggests a
diagnosis of PSC in adults.
3.2.2. Bile Duct Sclerosis. In long-standing sclerosing cholan-
gitis and also in other biliary diseases such as ischemic
cholangitis, the bile duct wall shows a marked deposition of
collagen ﬁber (bile duct sclerosis). The aﬀected bile ducts in
sclerosing cholangitis show a marked increase in the number
of c-kit receptor-expressing mast cells which secrete ﬁbro-
genicfactorssuchashistamine,basicﬁbroblastgrowthfactor
(bFGF), and/or tumour necrosis factor-alpha (TNF-α). The
biliary epithelium itself produces and secretes ﬁbrogenic
substances such as bFGF, transforming growth factor-beta
(TGF-β), and platelet-derived growth factor (PDGF), as well
as basement membrane proteins and extracellular matrix
proteins. In biliary atresia, BECs of the aﬀected bile ducts
variably express mesenchymal markers such as vimentin
and might have acquired phenotypes of mesenchymal cells,
though distinct morphological epithelial mesenchymal tran-
sition(EMT)ofbiliaryepitheliumishardlyrecognizable[28,
29]. In all forms of bile duct sclerosis, a marked attenuation
of the peribiliary vascular plexus is seen within the sclerotic
ductwall,butit remainsunknownwhetherthesechangesare
secondary to, or responsible for, the bile duct ﬁbrosis.
3.2.3. Bile Duct Loss or Ductopenia. The balance of cell
death or dropout due to apoptosis or necrosis and the
regeneration of lining biliary epithelia is important for
the maintenance of bile ducts, and apoptotic activity that
exceeds the proliferative response of bile duct cells results in
progressiveductopenia.Ductopeniaisdeﬁnedasalossofbile
ducts from the portal tract in which hepatic arterial branches
and bile ducts of similar size run parallel. Thus, portal
tracts without evident bile ducts indicate a loss of bile ducts.
Immunostaining of biliary cytokeratins such as CK7 and
CK19 is helpful for the recognition of bile ducts. Ductopenia
is usually deﬁned as the absence of interlobular bile ducts in
at least 50% of portal tracts. Extensive ductopenia is usually
associated with chronic cholestasis and biliary ﬁbrosis.
Ductopenia is typically found during chronic liver allograft
rejection with chronic cholestasis and also the advanced
stages of PBC.
3.2.4. Mucobilia and Hemobilia. Mucin is impacted in the
duct lumen and this is occasionally marked, leading to
leakageandextravasationwiththeformationofmucuslakes.
Drainage of mucin from Papilla of Vater is also a clinical
manifestation of mucobilia, as seen in intraductal papillary
mucinous neoplasms of the pancreas. Mucobilia is usually
found in the neoplastic bile ducts and nonneoplastic bile
ducts of “intraductal papillary neoplasms of the bile duct”
(formerly known as “biliary papillomatosis”) or mucin-
producing bile duct tumors [26, 30]. When such changes are
encountered in nonneoplastic biliary diseases such as PSC
and hepatolithiasis, usually microscopic neoplastic biliary
lesions are found in the aﬀected bile ducts.
In cases of hemobilia, impacted erythrocytes are encoun-
tered in bile duct lumens. Recent endoscopic or surgical
biliary manipulations in association with a primary or
secondary malignancy may be underlining diseases for
hemobilia.
3.2.5. Ductular Reaction. To date, many pathological terms
suchasovalcellproliferation,intermediatecells,andatypical
bile ductular proliferation have been used to describe the
“increased ductule-like cells or clusters of small epithelial
cells diﬀerent from mature hepatocytes” in the portal tract
or the periportal area. This is a reaction of the ductular
phenotype, possibly but not necessarily of ductular ori-
gin, commonly seen in many kinds of acute and chronic6 International Journal of Hepatology
Table 1: Etiologic classiﬁcation of cholangiopathy.
(1) Immune-mediated cholangiopathy
(2) Infectious cholangiopathy
(3) Genetic cholangiopathy
(4) Ischemic cholangiopathy
(5) Drug- or toxin-induced cholangiopathy
hepatobiliary diseases. Recently, an international working
group proposed the term “ductular reaction” for this lesion
[25]. “Ductular reaction” implies a reaction of ductular
phenotype, possibly but not necessarily of ductular origin.
Theepithelialcomponentofaductularreactionmayactually
derive from several sources: not only from the proximal
branches of the biliary tree but also from the circulation
(often if not always from bone marrow) and from biliary
metaplasia of hepatocytes. “Reaction” encompasses the com-
plex of stroma, inﬂammatory cells, and other structures of
diverse systems, all of which participate in the reactive lesion.
Bile ductular reaction is usually characterized by increased
numbers in the periportal and portal areas and a common
and frequent process in a number of hepatobiliary diseases.
A ductular reaction itself is heterogeneous in its devel-
opment and has many meanings. There are several reports
that bile ductules are very reactive anatomical elements in
the liver, and proliferated bile ductules are involved in the
progression of various chronic liver diseases. Our recent
studies showed that bile ductular cells in PBC, PSC, and
also NAFLD may undergo cellular senescence, and these
cells could produce and secrete biologically active molecules
and thereby be involved in hepatic ﬁbrogenesis and other
pathologic features of the liver.
3.2.6. Ductal Plate Malformation. Ductal plate malforma-
tions (DPMs), which are diﬀerent from reactive changes of
bile ducts or ductules, develop as a result of a remodeling
failure of the ductal plate followed by the development of
intrahepatic bile ducts. DPMs are characterized by increased
numbers of abnormal bile duct-like structures and show
a bridge-like structure in the dilated lumen and bulbar
protrusion of biliary epithelia [31]. DPMs are observed
in congenital hepatic ﬁbrosis and Caroli’s disease, biliary
atresia, and other ﬁbropolycystic liver diseases.
4.Cholangiopathies
Diseasesthatmainlytargetthebiliarytree(cholangiopathies)
canbe divided into severalcategoriesaccording to the patho-
genetic mechanism involved (Table 1). However, in many
cholangiopathies, more than one pathogenetic mechanism is
operative.
4.1. Immune-Mediated Cholangiopathies. The biliary tree
could be aﬀected by immunological assaults, and lym-
phoplasmacytic inﬁltration is evident around the damaged
bile ducts. Primary biliary cirrhosis (PBC) and primary
sclerosing cholangitis (PSC) are representative immune-
mediated cholangiopathies [32]. Autoimmune pathogenesis
is operative in PBC and PSC. There is a mixture of
immunocompetent cells in the aﬀected bile ducts, and
CD3+, CD4+, and CD8+ T cells that bear the T-cell receptor
α/β are predominant in PBC, supporting that Th1 immune
response-predominant cytotoxicity and/or cytokine release
are involved in the pathogenesis of the bile duct lesions
of PBC. HLA-class II antigens are aberrantly expressed in
the aﬀected bile ducts of PBC, PSC, and chronic allograft
rejection [33]. Biliary innate immunity is also involved in
the pathogenesis of cholangiopathies in patients with PBC
and biliary atresia (BA) [9]. BECs possess an innate immune
system consisting of the Toll-like receptor (TLR) family and
recognize pathogen-associated molecular patterns (PAMPs).
In PBC, CD4-positive Th17 cells characterized by the secre-
tion of IL-17 are implicated in the chronic inﬂammation of
bile ducts, and the presence of Th17 cells around bile ducts is
causally associated with the biliary innate immune responses
to PAMPs. In BA characterized by a progressive, inﬂam-
matory, and sclerosing cholangiopathy, dsRNA viruses are
speculated to be an etiological agent and to directly induce
enhanced biliary apoptosis via the expression of tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL).
Moreover, the epithelial-mesenchymal transition (EMT) of
biliary epithelial cells is also evoked by the biliary innate
immune response to dsRNA. In addition, intrahepatic small
bile ducts and bile ductules are a main target in graft-versus-
host disease and also hepatic allograft rejection. Recent
studies showed that IgG4-related sclerosing cholangitis is
also associated with altered immunity. Upregulation of
regulatory T cells (Tregs) associated with Th2 predominance
is reportedly important in the pathogenesis of IgG4-related
sclerosing cholangitis [3]. The anatomical level of the biliary
tree aﬀected is diﬀerent among these immune-mediated
cholangiopathies.Interestingly,theperibiliaryglandsarealso
involved in PSC, graft-versus-host disease, and IgG4-related
sclerosing cholangitis.
4.2. Infectious Cholangiopathies. The biliary tree is aﬀected
by several types of infectious diseases, such as bacterial,
fungal,protozoan,parasitic,andviralcholangitis.Stagnation
of bile due to biliary stenosis or obliteration is followed
by bacterial cholangitis, frequently with sepsis or abscess
formation. Parasitic infections are also reported in the
biliary tract including the liver, and liver ﬂukes such as
Clonorchis sinensis and Opisthorchis viverrini are endemic in
East Asia, particularly northern Thailand and some parts of
Korea, and cholangiocarcinoma is a serious complication of
parasitic cholangitis [26]. Hepatolithiasis is predominantly
a disease of the Far East and is causally also related to
infectious cholangitis, especially bacterial cholangitis [27,
34]. Mucin plays an important role in the development
of hepatoliths, which are formed within the intrahepatic
large bile ducts. Clinically, patients may present acutely
with recurrent bacterial cholangitis and its possible com-
plications, such as liver abscesses and septicemic shock, or
with chronic complications, such as cholangiocarcinomasInternational Journal of Hepatology 7
and intraductal papillary neoplasms [35]. Pathologically, it
is characterized by pigmented calcium bilirubinate stones
within dilated intrahepatic bile ducts featuring chronic
inﬂammation, mural ﬁbrosis, and proliferation of peribiliary
glands, without extrahepatic biliary obstruction. A transient
viral infection such as type A rhesus rotavirus and type 3
reovirus is reported as an initiating mechanism of biliary
atresia (BA), particularly perinatal type.
4.3. Genetic Cholangiopathies. Genetic alterations aﬀecting
the biliary tree manifest as biliary dilatation, bile duct
paucity, obstruction, proliferation, stone formation, and so
on. Caroli’s disease with congenital hepatic ﬁbrosis (CHF)
is a representative genetic cholangiopathy. Some cases of
biliary atresia (BA) also belong to this category. The former
is characterized by multiple saccular dilatations of the
intrahepatic bile ducts. Caroli’s disease with CHF belongs
to autosomal recessive polycystic kidney disease (ARPKD)
withductalplatemalformationcharacterizedbyadisordered
remodeling of the intrahepatic biliary tree [28]. Disordered
cell kinetics, including the apoptosis of biliary epithelial
cells (BECs), may be signiﬁcantly related to ductal plate
malformation, and laminin and type IV collagen levels were
reduced in the basement membrane of intrahepatic bile
ducts of ARPKD; such a reduction is an additional factor
for the dilatation of bile ducts. Paucity of the intrahepatic
bile ducts is a genetic cholangiopathy [36]. For example,
Alagille syndrome with a mutation in a ligand for the Notch
protein is characterized by paucity of intrahepatic bile ducts
and other anomalies. Cystic ﬁbrosis (CF) due to a mutation
in the cystic ﬁbrosis transmembrane conductance regulator
(CFTR) is associated with focal biliary ﬁbrosis, and the bile
duct and ductules are ﬁlled with pink and amorphous secre-
tions. Low phospholipid-associated cholelithiasis (LPAC) is
characterized by a low biliary phospholipid concentration
with symptomatic and recurring cholelithiasis, and LPAC
syndrome is associated with mutations of the adeno-
sine triphosphate-binding cassette, subfamily B, member
4 (ABCB4) gene encoding the hepatobiliary phospholipid
translocator multidrug resistance protein 3 [37]. This causes
recurrent cholelithiasis, continuous irritations of the biliary
tract with cholangitis, chronic cholestasis, and even biliary
cirrhosis.
4.4. Ischemic Cholangiopathies. Ischemic cholangiopathy is
deﬁned as focal or extensive damage to bile ducts due
to an impaired blood supply [11]. Most causes of bile
duct ischemia are iatrogenic, though some systemic vascular
diseases also cause this type of cholangiopathy. This entity
may be observed in various circumstances and is of clinical
importance for practitioners involved in gastroenterology,
oncology, abdominal surgery, and liver transplantation.
Ischemic bile duct injury may occur when small hepatic
arteries or the peribiliary vascular plexus are injured or when
all possible sources of arterial blood supply are interrupted.
Ischemic biliary injury may take the form of bile duct
necrosis, bile leakage, biloma, bile duct ﬁbrosis, or stenosis.
Bile duct necrosis and bilomas develop predominantly where
there is an abrupt and complete interruption of the arterial
blood supply, for example, when HA thrombose in a
liver transplant recipient. On the contrary, ﬁbrous stenoses
develop where there is progressive injury to the hepatic
arterioles, for example, after several courses of intra-arterial
chemotherapy. Cholangiographic ﬁndings include diﬀuse
and multiple bile ducts lesions. Ischemic cholangiopathy is a
serious complication during liver transplantation [4]. When
biliary drainage or reconstruction is not possible or has
failed, liver transplantation is the only potential cure.
4.5. Drug- or Toxin-Induced Cholangiopathies. Bile ducts,
particularly interlobular bile ducts, are occasionally aﬀected
by drug-induced hepatobiliary damage, various bile duct
injuries, various types of cholangitis, and bile duct loss
(drug-inducedcholangiopathy)[38].Thistypeofcholangitis
is not infrequently associated with cholestasis. Some cases
presenting with progressive ductopenia and cholangitis and
prolonged cholestasis mimic PBC and also PSC. While the
mechanism of drug-induced cholangitis remains speculative,
immune-mediated processes including hypersensitivity may
be operative. Some forms of drug-induced cholangiopa-
thy develop after hepatic arterial infusion of ﬂoxuridine
(FUDR) (ﬂoxuridine- (FUDR-) induced cholangiopathy).
Ischemic changes to the peribiliary vascular plexus may
be at least partly involved in this type of cholangiopa-
thy. Although BECs have low metabolic activity com-
pared with hepatocytes, cytotoxic or cytopathic bile duct
injury has been produced experimentally or accidentally
by toxic substances such as α-naphthylisothiocyanate, 4,4 -
diaminodiphenylmethane, and paraquat (toxin-induced
cholangiopathy) [18].
In conclusion, the anatomy and physiology of the
biliary tree, basic injuries to biliary epithelial cells, basic
forms of bile duct damage, and etiological classiﬁcation of
cholangiopathy were reviewed. This tutorial review will be
helpful for better understanding cholangiopathies.
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